Medicare AdvantageBilling CodesMedium impact
MA11.078e, Scar Revision
Independence Blue Cross·Dermatology, Plastic Surgery, General Surgery +1 more·Medical Policy
Effective date
Oct 1, 2026
We identified it
Oct 2, 2026
Summary
Independence Blue Cross Medicare Advantage updated MA11.078e effective 10/01/2026 with HCPCS code changes for scar revision treatment. The deleted code J9190 (fluorouracil 500 mg) has been replaced with two new codes: J9191 (fluorouracil avyxa 10 mg) and J9192 (fluorouracil 10 mg). Additionally, J3300 narrative was revised to specify the brand name (triesence) for triamcinolone acetonide. Billing teams must update systems to stop billing the old fluorouracil code and begin using the new codes for intralesional injections in keloid and hypertrophic scar treatment.
Action Required
By 09/30/2026: Billing team must update billing system to discontinue use of HCPCS code J9190 (fluorouracil 500 mg). Add new codes J9191 and J9192 to the system for fluorouracil intralesional injections used in scar revision treatment. Update J3300 documentation in the system to reflect the brand-specific descriptor (triesence) for triamcinolone acetonide. Communicate the code changes to providers performing scar revision procedures. Audit any pending claims using J9190 and rebill with appropriate new codes (J9191 or J9192) on or after 10/01/2026. Failure to make these updates will result in claim denials or rejections for fluorouracil injections billed after the effective date.